| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2007.
IN THIS ISSUE
| The first 10% of the full text of this article appears below. |
Transdermal Testosterone and Libido in Female Cancer Survivors
Female cancer survivors may suffer from low libido and other changes in sexual function. In previous trials, a combination of transdermal testosterone and estradiol has been shown to improve libido in women with low libido. To determine whether transdermal testosterone alone could benefit cancer survivors, Barton et al. (p. 672) measured serum testosterone levels and changes in sexual function reported by postmenopausal women who were cancer survivors. The participants were randomly assigned to transdermal testosterone or placebo in a randomized controlled trial with a crossover design. Although their
Drug Resistance and Genetic Instability in CML Stem Cells
HER2-Overexpressing Breast Cancer and Multiagent Targeted Treatment
Rituximab, Chemotherapy, and Overall Survival in Lymphoma Patients
New Risk Prediction Models for Lung Cancer
Long-term Results of Tamoxifen Treatment Trial to Prevent Breast Cancer
Related Articles in JNCI
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2007 99: 659-661.
J Natl Cancer Inst 2007 99: 662-663.
J Natl Cancer Inst 2007 99: 672-679.
J Natl Cancer Inst 2007 99: 680-693.
J Natl Cancer Inst 2007 99: 694-705.
J Natl Cancer Inst 2007 99: 706-714.
J Natl Cancer Inst 2007 99: 715-726.
J Natl Cancer Inst 2007 99: 727-737.